Published in Vaccine Weekly, June 22nd, 2005
"Therapeutic immunization with autologous monocyte-derived dendritic cells (DCs) loaded with heat-inactivated autologous human immunodeficiency virus type 1 (HIV-1) in 12 patients with chronic HIV-1 infection who were receiving highly active antiretroviral therapy (HAART) was feasible, safe, and well tolerated. Virus was obtained during an initial interruption of HAART (hereafter, 'stop 1') so that DCs could be pulsed. After immunization and a second interruption of HAART (hereafter, 'stop 2'), set-point plasma viral load (PVL; 24 weeks after...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly